{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:19:56Z","timestamp":1791206396315,"version":"4.1.0"},"reference-count":23,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[1999,10,1]],"date-time":"1999-10-01T00:00:00Z","timestamp":938736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[1999,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Besides direct bactericidal activity, long-term effectiveness is one of the most important features to consider when developing new drugs for chemotherapy. In this study, we evaluated the ability of rifapentine (RFP), in monotherapy and combination therapy, to completely eradicate a\n            <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n            infection and to prevent relapse posttreatment in a Swiss mouse model. The combination of RFP, isoniazid (INH), and pyrazinamide (PZA) administered daily resulted in an apparent clearance of\n            <jats:italic>M. tuberculosis<\/jats:italic>\n            organisms in the lungs and spleens of infected mice after 10 weeks of treatment. However, 3 months after the cessation of therapy, bacterial regrowth occurred in mice treated for a 12-week period, indicating a relapse of infection. In intermittent treatment regimens of RFP in combination with INH and PZA, sterilization was achieved when mice were treated two to five times per week for 9 weeks. Bacterial growth was still observed in the once-weekly treatment group. Our results show that mouse models can predict important parameters for new drugs. We stress the necessity for long-term posttreatment observation in animal models for the routine evaluation of new drugs for antituberculosis chemotherapy.\n          <\/jats:p>","DOI":"10.1128\/aac.43.10.2356","type":"journal-article","created":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T00:33:30Z","timestamp":1539045210000},"page":"2356-2360","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":27,"title":["Evaluation of Rifapentine in Long-Term Treatment Regimens for Tuberculosis in Mice"],"prefix":"10.1128","volume":"43","author":[{"given":"Anne M. J. A.","family":"Lenaerts","sequence":"first","affiliation":[{"name":"<!--label omitted: 1-->Department of Medicine, Veterans Affairs Medical Center, and Department of Medicine, State University of New York Health Science Center, Syracuse, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon E.","family":"Chase","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Department of Medicine, Veterans Affairs Medical Center, and Department of Medicine, State University of New York Health Science Center, Syracuse, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex J.","family":"Chmielewski","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Department of Medicine, Veterans Affairs Medical Center, and Department of Medicine, State University of New York Health Science Center, Syracuse, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Cynamon","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Department of Medicine, Veterans Affairs Medical Center, and Department of Medicine, State University of New York Health Science Center, Syracuse, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.11.3047"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.150.5.7952564"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.28.3.440"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/0962-8479(92)90066-S","article-title":"Activity of two long-acting rifamycins, rifapentine and FCE 22807, in experimental murine tuberculosis.","volume":"73","author":"Dhillon J.","year":"1992","unstructured":"Dhillon J. Dickinson J. M. Guy J. A. Ng T. K. Mitchison D. A. Activity of two long-acting rifamycins, rifapentine and FCE 22807, in experimental murine tuberculosis. Tuber. Lung Dis. 73 1992 116 123","journal-title":"Tuber. Lung Dis."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/145.1.212"},{"key":"e_1_3_2_7_2","first-page":"372","article-title":"Viable but nonculturable.","volume":"64","author":"Dixon B.","year":"1998","unstructured":"Dixon B. Viable but nonculturable. ASM News 64 1998 372 373","journal-title":"ASM News"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/0962-8479(95)90521-9","article-title":"Mycobacterial dormancy.","volume":"76","author":"Gangadharam P. R. J.","year":"1995","unstructured":"Gangadharam P. R. J. Mycobacterial dormancy. Tuber. Lung Dis. 76 1995 477 479","journal-title":"Tuber. Lung Dis."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.157.5.9709072"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/148.6_Pt_1.1541"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.12.2809"},{"key":"e_1_3_2_12_2","unstructured":"Kirk\n              R. E.\n          Experimental design: procedures for the behavioral sciences.\n          1986\n          Brooks-Cole Publishing Co.\n          Belmont Calif"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.2.298"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.10.2245"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.7.1476"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0041-3879(91)90017-M"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.123.3.445"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.11.2655"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.9.2073"},{"key":"e_1_3_2_20_2","first-page":"729","article-title":"Pathogenesis of a first episode of chronic pulmonary tuberculosis in man: recrudescence of residuals of the primary infection or exogenous reinfection?","volume":"95","author":"Stead W. W.","year":"1967","unstructured":"Stead W. W. Pathogenesis of a first episode of chronic pulmonary tuberculosis in man: recrudescence of residuals of the primary infection or exogenous reinfection? Am. Rev. Respir. Dis. 95 1967 729 745","journal-title":"Am. Rev. Respir. Dis."},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"731","DOI":"10.7326\/0003-4819-68-4-731","article-title":"The clinical spectrum of primary tuberculosis in adults. Confusion with reinfection in the pathogenesis of chronic tuberculosis.","volume":"68","author":"Stead W. W.","year":"1968","unstructured":"Stead W. W. Kerby G. R. Schleuter D. P. Jordahl C. W. The clinical spectrum of primary tuberculosis in adults. Confusion with reinfection in the pathogenesis of chronic tuberculosis. Ann. Intern. Med. 68 1968 731 745","journal-title":"Ann. Intern. Med."},{"key":"e_1_3_2_22_2","first-page":"A467","article-title":"Update on US Public Health Service (USPHS) study 22: a trial of once weekly isoniazid (INH) & rifapentine (RFP) in the continuation phase of TB treatment.","volume":"157","author":"Vernon A.","year":"1998","unstructured":"Vernon A. Khan A. Bozeman L. Wang Y. C. Update on US Public Health Service (USPHS) study 22: a trial of once weekly isoniazid (INH) & rifapentine (RFP) in the continuation phase of TB treatment. Am. J. Respir. Crit. Care Med. 157 1998 A467","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02111491"},{"key":"e_1_3_2_24_2","unstructured":"World Health Organization\n          Treatment of tuberculosis: guidelines for national programmes 2nd ed. World Health Organization publication no. TB\/97.220.\n          1997\n          World Health Organization\n          Geneva Switzerland"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.43.10.2356","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.43.10.2356","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T15:57:49Z","timestamp":1645459069000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.43.10.2356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,10]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[1999,10]]}},"alternative-id":["10.1128\/AAC.43.10.2356"],"URL":"https:\/\/doi.org\/10.1128\/aac.43.10.2356","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,10]]},"assertion":[{"value":"1999-05-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"1999-07-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"1999-10-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}